Your browser does not support JavaScript! Aspyre® Lung Reagents | Biofidelity

Globally decentralized biomarker testing.

A scientist inserts a sample into a PCR machine.


Local, cost-effective biomarker testing in any lab.

The first research use only (RUO) application of our groundbreaking Aspyre technology, Aspyre Lung Reagents are designed to run on the existing global network of qPCR platforms, and can be seamlessly integrated into existing lab workflows anywhere in the world at a fraction of the cost of NGS.



Simultaneously analyze DNA and RNA from tissue or blood.

Easy to adopt and even easier to interpret, with turnkey data analysis, Aspyre Lung Reagents simultaneously analyze DNA and RNA from tissue or blood, maximizing the opportunity to identify mutations and fusions, while avoiding the additional time and expense of running separate assays.


A laboratory scientist examines a sample through a microscope.

Aspyre Lung Reagents packaging

Integrate seamlessly into your existing workflow.

The key to decentralized genomic testing, Aspyre Lung Reagents are designed to be integrated into your lab’s workflow with minimal staffing and instrumentation requirements.

Fast, simple, reliable biomarker testing on samples you control.

Using a simple, 4-step workflow on qPCR platforms, Aspyre Lung Reagents can deliver results in hours from 114 variants across 11 genes, including DNA and RNA biomarkers, to aid in NSCLC research.

A simple, 4-step workflow on existing qPCR platforms (currently optimized on QS5 384). Simple, targeted biomarker data, with minimal data handling and storage requirements.

Aspyre Lung Reagents can provide results in hours, enabling rapid input into NSCLC research.

100% specificity, with the ability to consistently generate results from poor quality samples.

With simple integration into your lab, Aspyre Lung Reagents enable lightning-fast analysis on samples you control.

No need for complex bioinformatics. Biofidelity provides fast, simple cloud-based software at no additional cost.

Simultaneously analyze DNA & RNA from tissue or blood, maximizing the opportunity to identify mutations and fusions, while avoiding the time and expense of running separate assays or missing fusion positive samples.

Coverage of 114 variants across 11 genes, including DNA and RNA biomarkers

Simple setup & consistent performance across sites, including challenging sample types

Multi-site Concordance

  • Fast setup at University of Pennsylvania and Medical College of Wisconsin
  • 54 FFPE tissue samples analyzed at University of Pennsylvania, Medical College of Wisconsin and Biofidelity
  • Excellent concordance between sites

Challenging Sample Types

  • 16 additional ‘challenging’ cytology samples tested at all sites
  • Included peritoneal fluid, pleural effusions, fine needle aspirates (FNAs) & FNA washes

Aspyre Lung Reagents by the numbers

100%

Specificity
DNA (SNVs & Indels)



1.10%

Median panel-wide limit of detection 95%
DNA (SNVs & Indels)



100%

Specificity
RNA (Fusions)



8

Amplifiable copies
Median panel-wide limit of detection 95% RNA (Fusions)



100%

Specificity
MET Exon 14 Skipping


262

Amplifiable copies
MET Exon 14 Skipping


100%

Specificity
DNA (SNVs & Indels)



0.19%

Median panel-wide limit of detection 95%
DNA (SNVs & Indels)



100%

Specificity
RNA (Fusions)



1

Amplifiable copy
Median panel-wide limit of detection 95% RNA (Fusions)



100%

Specificity
MET Exon 14 Skipping


69

Amplifiable copies
MET Exon 14 Skipping


Aspyre Clinical Test for Lung

The first clinical application of the Aspyre technology, Aspyre Clinical Test for Lung provides fast, actionable biomarker data for non-small cell lung cancer (NSCLC) patients.

Learn more